Crossref
Phase I and Phase II Evaluation of Novel Anticancer Agents: Are Response and Toxicity the Right Endpoints?
Onkologie · 2000
DOI: 10.1159/000055040 ↗Kurz gefasst
Fachartikel in der Zeitschrift Onkologie, 2000. Verfasst von E.A. Eisenhauer.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Eisenhauer, E. (2000). Phase I and Phase II Evaluation of Novel Anticancer Agents: Are Response and Toxicity the Right Endpoints?. Onkologie. https://doi.org/10.1159/000055040
Vancouver
Eisenhauer E. Phase I and Phase II Evaluation of Novel Anticancer Agents: Are Response and Toxicity the Right Endpoints?. Onkologie. 2000. doi:10.1159/000055040
BibTeX
@article{Eisenhauer2000,
author = {Eisenhauer, E.A.},
title = {Phase I and Phase II Evaluation of Novel Anticancer Agents: Are Response and Toxicity the Right Endpoints?},
journal = {Onkologie},
year = {2000},
doi = {10.1159/000055040}
}
EUVIMED